Dr. Michael Herbig
Michael Herbig has 20 years of experience in pharmaceutical development with a focus on topical dermatological dosage forms and special drug delivery systems. His experience ranges from concept design and confirmatory development to industrialization. He studied pharmaceutical sciences at the University of Würzburg, received his doctorate in drug delivery at the Pharmaceutical Institute of ETH Zurich, Switzerland, and holds an MBA (Open University Business School, UK). For his degree in pharmacy he was awarded the prize of the Faculty of Chemistry and Pharmacy; for his doctorate he received the prize of the Society of Swiss Industrial Pharmacists (GSIA).
He began his career at Novartis AG in Basel with positions of increasing responsibility in NCE preformulation and pharmaceutical development. Later he was head of formulation development and then head of pharmaceutical development at Almirall Hermal in Reinbek, Germany.
In his functions, he and his teams have created an API-centered, rational, risk-based formulation design based on a thorough physicochemical understanding of the drug formulations. Furthermore, they developed procedures for reliable prediction of chemical and physical stability as well as strategies and models for investigating and modifying skin penetration.
Furthermore, he has extensive knowledge regarding regulatory requirements for pharmaceuticals (GMP, ICH) and the economic implications of formulation design with regards to process and transfer risks, manufacturing, operating and investment costs.
Michael is the author of a number of publications in renowned journals and the inventor of several granted patent families in the field of pharmaceutical formulations. He regularly gives invited talks as well as guest lectures at universities. He has worked in Germany, France, Spain and Switzerland and speaks German, English and Spanish.
Dr. Melanie Köllmer
Dr. Melanie Köllmer is head of formulation development at RaDes. She has more than 10 years of experience in pharmaceutical and biomedical research. Her expertise lies in the implementation of development projects, from formulation design of semi-solid dosage forms in feasibility studies to clinical phase and process development.
She studied pharmacy at Philipps-University in Marburg, Germany, and received her PhD in drug delivery and tissue engineering from the University of Illinois at Chicago, USA, in the laboratory of Prof. Dr. Richard A. Gemeinhart, followed by a PostDoc at the Illinois Institute of Technology (IIT) in Prof. Dr. Eric Brey’s laboratory.
Subsequently, Melanie worked as a formulation scientist at Almirall Hermal. In close cooperation with analytical development as well as drug discovery, the IP and Regulatory Affairs departments, she worked extensively on the design of semi-solid formulations and the evaluation of new topical excipients and technology platforms. In particular, she made decisive contributions to the successful development of a stable aqueous tacrolimus cream (Patent WO2019233722).
She focuses on rational design, cosmetic optimization, and characterization of semi-solid formulations for small molecules and probiotics. A special focus is the use of modern rheological methods to optimize stability, manufacturing processes and user friendliness of formulations.
Melanie Köllmer is the author of currently nine publications in the field of drug delivery and in vitro performance testing and regularly gives presentations in the field of formulation development and rheology.
Dirk Evers
Dirk Evers leads the analytical development of RaDes GmbH. He is a chemical engineer and has more than 25 years of experience in pharmaceutical analytics, in particular of semi-solid and liquid dosage forms. For these, he has provided analytical support for a variety of development and market products.
His work focuses on the development and validation of analytical methods for active pharmaceutical ingredients, their degradation products, and excipients, including the associated extraction processes. He has successfully established numerous new analytical technologies, in particular various mass spectrometric methods, for the determination of structural information of unknown degradation products. He also has rich experience in trouble shooting.
In addition, he has made important contributions to excipient characterization, in particular to innovative methods of polysorbate analysis in biopharmaceutical formulations, which are also described in several publications. These methods can help to optimize protein formulation in terms of stability and safety.
He developed methods to carry out precise calculations of the expected shelf lives based on quantification of degradation products. The predictions have proven to be very reliable and have contributed to the targeted optimization of many products. He has in-depth knowledge of statistical methods for data evaluation and for DoE-based optimization of chromatographic methods.
Prior to co-founding RaDes, Dirk held the position of Leader Analytical Science and Preformulation at Almirall Hermal. He also has extensive knowledge of regulatory requirements for pharmaceuticals (GMP, ICH).
Our values
We are motivated and dedicated to contributing to the development of medicines that help to improve patients’ quality of life and alleviate suffering.
From many years of experience in the development of dermatological medicines, we know that good products make an important contribution to patients’ quality of life. Having the opportunity to contribute to this is an important aspect of our daily motivation.
Dermatological diseases are rarely life-threatening (and rarely contagious), but are strongly perceived by the patient – both directly through the skin as the human‘s largest sensory organ, as well as indirectly through their manifestation on the skin, that is often visible to others which can have a stressful effect.
Dermatological formulations are literally “closer” to the user than most other medicines and well-developed products can – even beyond the clinical efficacy measured in studies – contribute significantly to therapeutic success and quality of life. Comfortable and safe handling, good tolerability considering the specific skin condition and pleasant cosmetics can support this. Above all, however, our contribution to progress is to solve challenging formulation tasks at all in order to bring promising active pharmaceutical ingredients to the market and make them available to patients. We are committed to this with all our knowledge, creativity and perseverance.
We use processes that conserve resources as much as possible and incorporate sustainability into our product design.
As a development service provider, RaDes does not manufacture any products and therefore consumes few resources.
The most important consumables are eluents for chromatography, i.e., organic solvents such as acetonitrile, methanol, or isopropanol. RaDes deliberately prioritizes the use of UPLC (ultra-high-performance liquid chromatography), which consumes approximately 80% less eluent than conventional HPLC. We also rely on miniaturization wherever possible to keep the amounts of active ingredients and other materials used as low as possible, for example in solubility screenings.
Another way to contribute to sustainability is to prioritize the design of sustainable products that are more resource-efficient in commercial manufacturing later on. For topical skin medications, this can be achieved in particular through efficient delivery systems. This allows a larger proportion of the active ingredient applied to the skin to be absorbed, thereby reducing the required dose and, consequently, potential negative environmental impacts. Other ways to influence product sustainability include selecting sustainable excipients and developing manufacturing processes that are less energy-intensive.
We believe that the commitment to continuous improvement, perseverance and the determination to solve even difficult problems are important success factors and we live this attitude.
Semi-solid dosage forms are diverse, often complex, and account for a rather small proportion of the total number of dosage forms developed. Therefore, many of these systems, including the classic cream, are generally less well understood than e.g. tablets or capsules. This makes it more challenging to develop them systematically, robustly and economically. In decades of experience, the RaDes team has not only developed many formulations, but has always invested in a better scientific-technical understanding of the basic principles of topical formulations. This knowledge allows us a largely “rational design” of formulations, i.e. a systematic, target-oriented procedure through which erroneous paths and subsequent changes can be minimized. In this way we also obtain answers why something works or not so that set-screws for specific modifications can be identified. It also provides the basis for innovations and enables us to solve even toughest challenges in formulation design and analytics. We are also convinced that such a systematic understanding of formulations means considerable economic saving potential in the medium and long term, as trouble shooting at a later stage can be avoided or carried out much more specifically.
Based on our experience, we firmly believe that lively scientific curiosity and persistent efforts to find better solutions pay off. In collaboration with universities, suppliers and partner companies, we continue to work on deepening this understanding to deliver the best possible solutions.
We want to make a positive contribution to the society by acting responsibly, professionally and fairly.
We have decided to start a business because we are ready to take responsibility and appreciate being in tune with our beliefs.
Inspired by the mission statement of the “honorable Hanseatic merchant”, fairness, reliability and long-term orientation are just as important to us as the endeavor to generate sustainable win-win situations with our business partners and to bear social responsibility.
We want to create jobs and to give our employees the opportunity to grow based on their individual strengths. Likewise, we are committed to contributing to scientific progress in our field through research and active participation in discourse.
Team
Dr. Michael Herbig, MBA, Co-Founder and CEO RaDes GmbH
Dr. Michael Herbig is a pharmacist, holds a PhD in “Drug Delivery & Formulation” from ETH Zurich, Switzerland, and an MBA from OUBS, UK. He began his career in formulation development at Novartis AG in Basel and was most recently Head of Pharmaceutical Development at Almirall Hermal GmbH.

Dirk Evers, Engineer (Dipl.-Ing. [FH]), Co-Founder and Head of Analytical Development
Dirk Evers is a chemical engineer with more than 25 years of experience in the analytics of pharmaceuticals and cosmetics. He has implemented a number of methods to optimize the analysis of semi-solid dosage forms. In addition, he made important contributions to the development of analytical methods for complex excipients.

Dr. Melanie Köllmer, Co-Founder and Head of Formulation Development
Dr. Melanie Köllmer is a pharmacist and holds a PhD in drug delivery from the University of Illinois at Chicago, USA. She has over ten years of experience in pharmaceutical research and development, in particular in the development of innovative topical formulations and rheological characterization.

Sascha Gorissen, Engineer (Dipl.-Ing. [FH]), Co-Founder and Head of Project Management
Sascha Gorissen is a biotechnology engineer with extensive experience in preclinical development, pharmaceutical analytics and project management. In addition to his role as head of laboratory and project management, he is responsible for the in vitro models of skin permeation.

Dr. Petra Lohmann, head of quality assurance
Dr. Petra Lohmann is a chemist and pharmacist with a PhD in pharmaceutical chemistry. She fulfils the requirements as a qualified person (QP) according to Directive 2001/83 EC with over 20 years of industrial experience in the field of pharmaceuticals and medical devices, most recently in leading positions in quality control and quality assurance.

Dr. Elina Hagelskamp, Senior Analytical Scientist
Dr. Elina Hagelskamp studied chemistry at LMU Munich and completed her Master’s degree with distinction. In her PhD project on organic analytical chemistry she gained expertise in various applications of chromatography and mass spectrometry. She joined RaDes in 2021 and her focus is analytical method development, stability investigations, in vitro release & permeation testing and analytical project lead.

Felix C. Wolf, Formulation Scientist
Felix C. Wolf is a registered pharmacist with a degree from the University of Greifswald. As pharmacist in the year of practical training at RaDes, he has already gained experience in DoE-based formulation design and rheological characterization of formulations. In his role as Formulation Scientist, he is now responsible for the design, manufacture and characterization of formulations. A particular focus is the rheological evaluation of semi-solid preparations.

Lina Kühn, Analytical Scientist
Lina Kühn holds a master’s degree in Pharmaceutical Biotechnology from the Hamburg University of Applied Sciences. In parallel to pursuing her degree, she gained experience with GC-MS in a bioanalytical laboratory and with UPLC in the quality control of topically applied pharmaceuticals. At RaDes, her areas of focus include analytical method development, stability studies, in vitro models such as IVRT and IVPT, and ex vivo performance models for bioavailability in the skin, nails, and eyes.

Janek Giebel, Senior Laboratory Technician
Janek Giebel is a chemical laboratory technician and joined RaDes in 2019. Thanks to his apprenticeship, which he completed with distinction as one of the best of the year, he was already very familiar with the analysis of semi-solid dosage forms. His focus at RaDes is sample preparation and analytics of semi-solid formulations, chromatography with UV/Vis and mass spectrometric detection, and analytics of complex excipients.

Sabine Fielhauer, Laboratory Technician
Sabine Fielhauer is a trained chemical laboratory technician and has over 35 years of practical experience in the galenic development of semi-solid formulations. She has been involved in many process transfers from development to production scale and is co-inventor of several patents and co-developer of various market products. Her main focus at RaDes is the manufacturing and characterization of formulations as well as their process development.

Sajedeh Bagheri, Laboratory Technician Formulation
Sajedeh Bagheri has bachelor’s degree in biochemistry from Azad University Mashhad, Iran, and has studied a Master in Cosmetic Science at the University of Hamburg, pending formal completion. She has gained industry experience in the manufacturing and characterization of semi-solid formulations. She brings a combination of science-based formulation development and expertise in optimizing their cosmetic properties.

Ariane Hartmann, Senior Laboratory Technician Analytics
Ariane Hartmann is a Chemical Laboratory Technician with over 10 years of experience in analytical development. Her expertise and hands-on experience include HPLC and UPLC method development with UV and MS detection, as well as instrument maintenance. Ariane joins us from Sigma-Aldrich/Merck KGaA. Her focus is analytical method development, stability studies, and in vitro & ex vivo models.

Katja Hepenstrick, Administrative Assistant (part-time)
Katja Hepenstrick has extensive experience as an executive assistant, secretary, and administrative specialist in various industries. At RaDes, she is in charge of preparatory accounting, invoicing, and general organizational matters.

Publications
- Lunter D, Gorissen S, Herbig ME, Hukauf M, Eichner A, Reflection paper on the APV workshop on in vitro performance testing of topically applied and topically acting substances, Eur J Pharm Biopharm (220), 2026, 114971
- Surber C, Herbig ME, Reinau-Häberlin D, The Crux of vehicle designations: The essence of topical dermatologic vehicles and their use, Journal of Pharmaceutical Sciences, 2025, 104109
- Evers DH, Giebel J, Nienau F, Carle S, Gorissen S, Buske J, Herbig ME, Garidel P, Hagelskamp E, Unravelling the polysorbate 20 composition: A fusion of UPLC-MS analysis and stochastic modelling, Eur J Pharm Biopharm (216), 114854, 2025
- Schoenfelder H, Reuter M, Evers D, Herbig ME, Lunter DJ, Ceramide Profiling of Porcine Skin and Systematic Investigation of the Impact of Sorbitan Esters (SEs) on the Barrier Function of the Skin. Molecular Pharmaceutics, 22 (4), 2019-2028, 2025
- Hsiao W-K, Herbig ME, Newsam JM, Gottwald U, May E, Winckle G, Birngruber T. Opportunities of topical drug products in a changing dermatological landscape. European Journal of Pharmaceutical Sciences, Volume 203, 106913, 2024
- Carle S, Evers DH, Hagelskamp E, Garidel P, Buske J. All-in-one stability indicating polysorbate 20 degradation root-cause analytics via UPLC-QDa, Journal of Chromatography B, Volume 1232, 2024,123955
- Herbig ME, Evers DH, Gorissen S, Köllmer M. Rational Design of Topical Semi-Solid Dosage Forms-How Far Are We? Pharmaceutics 15, 1822, 2023
- Sailer MM, Köllmer M, Masson B, Fais F, Hohenfeld IP, Herbig ME, Koitschev AK & Becker S. Nasal residence time and rheological properties of a new bentonite-based thixotropic gel emulsion nasal spray – AM-301, Drug Development and Industrial Pharmacy, 2023
- Herbig, ME. Topical Drug Delivery and the Role of Excipients, Chimica Oggi – Chemistry Today, 40 (6), 34-37, 2022
- Fronk V, Schäffler M, Bonyadi H, Herbig ME, Köllmer M, Die Produktion pharmazeutischer Emulsionen optimieren. Nachrichten aus der Chemie, 70, 49-51, 2022
- Kapoor K, Gräfe N, Herbig ME, Topical film-forming solid solutions for enhanced dermal delivery of the retinoid tazarotene, Journal of Pharmaceutical Sciences, (111), 2779-2787, 2022
- Evers DH, Carle S, Lakatos D, Hämmerling F, Garidel P, Buske J. Hydrolytic polysorbate 20 degradation – Sensitive detection of free fatty acids in biopharmaceuticals via UPLC-QDa analytics with isolator column, Journal of Chromatography B, Volume 1174, 2021, 122717.
- Evers DH, Schultz-Fademrecht T, Garidel P, Buske J. Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection, Journal of Chromatography B, Volume 1157, 2020, 122287.
- Puschmann J, Evers DH, Müller-Goymann CC, Herbig ME. Development of a Design of Experiments optimized method for quantification of polysorbate 80 based on oleic acid using UHPLC-MS. J. Chrom. A, (1599): 136-143, 2019.
- Puschmann J, Herbig ME, Müller-Goymann CC. Influence of emulsifier concentration on partition behavior and chemical stability of betamethasone dipropionate in emulsion gels. Int. J. Pharm, (562): 105-112, 2019.
- Köllmer M, Mossahebi P, Sacharow E, Gorissen S, Gräfe N, Evers DH, Herbig ME. Investigation of the Compatibility of the Skin PAMPA Model with Topical Formulation and Acceptor Media Additives Using Different Assay Setups. AAPS PharmSciTech, 20(89), 2019.
- Puschmann J, Herbig ME, Müller-Goymann CC. Correlation of antimicrobial effects of phenoxyethanol with its free concentration in the water phase of o/w-emulsion gels. Eur J Pharm Biopharm, (131): 152–161, 2018.
- Blenner SR, Köllmer M, Rouse AJ, Daneshvar N, Williams C, Andrews LB. Privacy Policies of Android Diabetes Apps and Sharing of Health Information. JAMA, 315(10): 1051-52, 2016.
- Herbig ME, Houdek P, Gorissen S, Brandner J et al. A custom tailored model to investigate skin penetration in porcine skin and its comparison with human skin. Eur J Pharm Biopharm, (95): 99-109, 2015.
- Köllmer M, Appel A, Somo S, Brey E. Long-Term Function of Alginate Encapsulated Islets. Tissue Engineering Part B: Reviews, 22(1), 2015. DOI: 10.1089/ten.TEB.2015.0140.
- Sharma V, Köllmer M, Szymusiak M, Nitsche LC, Gemeinhart RA, Liu Y. Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme. Biomacromolecules, 15(3): 756-62, 2014.
- Zhang Y, Köllmer M, Buhrman JS, Tang MY, Gemeinhart RA. Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential. Peptides, 58: 83-90, 2014.
- Herbig ME, Evers DH. Correlation of hydrotropic solubilization by urea with log D of drug molecules and utilization of this effect for topical formulations. Eur J Pharm Biopharm, 85(1): 158-160, 2013.
- Köllmer M, Buhrman JS, Zhang Y, Gemeinhart RA. Markers Are Shared Between Adipogenic and Osteogenic Differentiated Mesenchymal Stem Cells. Journal of Developmental Biology and Tissue Engineering, 5(2): 18-25, 2013.
- Köllmer M, Popescu C, Manda P, Zhou L, Gemeinhart RA. Stability of Benzocaine Formulated in Commercial Oral Disintegrating Tablet Platforms. AAPS PharmSciTech, 14(4):1333-40, 2013.
- Köllmer M, Keskar V, Hauk TG, Collins JM, Russell B, Gemeinhart RA. Stem Cell-Derived Extracellular Matrix Enables Survival and Multilineage Differentiation within Superporous Hydrogels. Biomacromolecules, 13(4): 963-973, 2012.
- Buhrman JS, Rayahin JE, Köllmer M, Gemeinhart RA. In-house preparation of hydrogels for batch affinity purification of glutathione S-transferase tagged recombinant proteins. BMC Biotechnology, 12(1): 63, 2012.
- Herbig ME, Weller K, Merkle HP. Reviewing biophysical and cell biological methodologies in cell penetrating peptide research. Critical Rev. in Therapeutic Drug Carrier Systems, 24(3): 203-255, 2007.
- Herbig ME, Assi F, Textor M, and Merkle HP. The cell penetrating peptides pVEC and W2-pVEC induce transformation of gel phase domains in phospholipid bilayers without affecting their integrity. Biochemistry, 45(11): 3598-3609, 2006.
- Herbig ME, Weller K, Krauss U, Beck-Sickinger AG, Merkle HP, and Zerbe O. Membrane surface-associated helices promote lipid interactions and cellular uptake of human calcitonin-derived cell penetrating peptides. Biophysical Journal, 89(6): 4056-4066, 2005.
- Herbig ME, Fromm U, Leuenberger J, Krauss U, Beck-Sickinger AG, and Merkle HP. Bilayer interaction and localization of cell penetrating peptides with model membranes. Biochimica et Biophysica Acta-Biomembranes, 1712(2): 197-211, 2005.
About RaDes
RaDes – Rational Design of Formulations – offers consulting and development services for the pharmaceutical and cosmetic industry. We are a team of scientists with outstanding expertise in the field of semi-solid and liquid dosage forms, with in-depth knowledge of the procedures, guidelines and decision-making processes in the pharmaceutical industry from concept development to industrialization.
In addition to the scientific and technical aspects, we also have extensive experience in dermatology and dermatological cosmetics regarding regulatory, clinical, pre-clinical, patent and marketing aspects.
We are a strong partner for the toughest development challenges as well as for fast, flexible and efficient solutions for various development and consulting tasks.
RaDes GmbH, based in Hamburg, was founded in July 2018 by Dr. Michael Herbig, previously head of pharmaceutical development at Almirall Hermal GmbH and former formulation developer at Novartis AG in Basel, together with the experienced scientists Dr. Melanie Köllmer, Dirk Evers and Sascha Gorissen.

Imprint
Contact details
RaDes GmbH
Schnackenburgallee 114
D-22525 Hamburg
Mail: info@rades-development.com
Authorized: Dr. Michael E. Herbig, managing director
Address as above.
Register and register number: District Court Hamburg, HRB 152151
VAT registration number: DE319530136
Privacy Statement
With this privacy statement we would like to inform you about the collection of personal data when using our website.
1. Personal data
Personal data within the meaning of Art. 4 of the EU General Data Protection Regulation (DSGVO) are all information relating to an identified or identifiable natural person, eg. Name, address and e-mail address.
2. Responsible
Responsible for the processing of personal data within the meaning of Art. 4 (7) DSGVO is RaDes GmbH, Schnackenburgallee 114, 22525, Hamburg (info@rades-development.com).
3. Collection and processing of personal data when visiting our website
When you visit our website, we collect only the personal data that your browser transmits to our server and that are technically necessary for the presentation of our website and the guarantee of stability and security.
Legal basis is Art. 6 1 b) GDPR.
Cookies
Some of our web pages use cookies. Cookies do not harm your computer and do not contain any viruses. Cookies help make our website more user-friendly, efficient, and secure. Cookies are small text files that are stored on your computer and saved by your browser.
Most of the cookies we use are so-called “session cookies.” They are automatically deleted after your visit. Other cookies remain in your device’s memory until you delete them. These cookies make it possible to recognize your browser when you next visit the site.
You can configure your browser to inform you about the use of cookies so that you can decide on a case-by-case basis whether to accept or reject a cookie. Alternatively, your browser can be configured to automatically accept cookies under certain conditions or to always reject them, or to automatically delete cookies when closing your browser. Disabling cookies may limit the functionality of this website.
Cookies which are necessary to allow electronic communications or to provide certain functions you wish to use (such as the shopping cart) are stored pursuant to Art. 6 paragraph 1, letter f of DSGVO. The website operator has a legitimate interest in the storage of cookies to ensure an optimized service provided free of technical errors. If other cookies (such as those used to analyze your surfing behavior) are also stored, they will be treated separately in this privacy policy.
Server log files
The website provider automatically collects and stores information that your browser automatically transmits to us in “server log files”. These are:
- Browser type and browser version
- Operating system used
- Referrer URL
- Host name of the accessing computer
- Time of the server request
- IP address
These data will not be combined with data from other sources.
4. Contact
When contacting us by e-mail, the information you provide (your e-mail address, your name and telephone number or any other personal information you have provided) will be stored by us to answer your questions or for ours Comply with business needs for communication. We delete the data arising in this context again after the storage is no longer necessary, provided that there are no statutory storage requirements or statute of limitations must be observed.
Legal basis is Art. 6 (1) (b) GDPR.
5. Rights of the person concerned
As data subject, you have the following rights regarding your personal data:
- Right to information,
- Right to rectification or erasure,
- Right to restriction of processing,
- Right to object to processing,
- Right to Data Portability.
You also have the right to complain to us about the processing of your personal data by a data protection supervisory authority.
6. Transfer to authorities
In the event of a legal obligation, we reserve the right to disclose information about you if we are required to disclose it to lawful authorities or law enforcement agencies.
Partners

Waters Corporation is the world’s leading specialty measurement company focused on improving human health and well-being through the application of high-value analytical technologies and industry leading scientific expertise.

ChiroBlock is a chemical R&D company at the intersection between basic research and industrial product development.
We develop first synthetic routes to new molecules and optimize them according to market requirements (custom synthesis services (mg-kg) & chemical process development).

Anton Paar develops, manufactures, distributes, and provides application know-how, support and service for analytical instruments used in research, development and quality control for laboratory and process applications worldwide.
The company, with more than 3,400 employees in over 110 countries, is constantly breaking new ground to combine high-precision engineering with scientific curiosity.

Chromicent GmbH is a pharmaceutical service provider in the Technology Park Berlin-Adlershof. The company specializes in analytical method development, validation and release testing of dosage forms and holds GMP certification from the Berlin Medicines Surveillance. The company is well connected and has over 50 pharmaceutical companies from Europe and the US among its customers.
MICHAEL HERBIG
MELANIE KÖLLMER
DIRK EVERS